Anti-amyloid monoclonal that achieved 27% slowing on CDR-SB; led to traditional FDA approval July 2023. Defined the post-amyloid AD-disease-modifying era.
Details
- nct_id
- NCT03887455
- phase
- phase_3
- status
- completed
- domain
- alzheimers
- indication
- Early Alzheimer's Disease
- intervention
- Lecanemab (anti-amyloid monoclonal)
- sponsor
- Eisai / Biogen
- n_enrolled
- 1795
- primary_endpoint
- CDR-Sum of Boxes change from baseline at 18 months
Raw fields (1)
- metadata
{}